Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Century Therapeutics, Inc.NASDAQ: IPSC

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue remains negative

Q1 FY2026 deferred revenue was $0, compared with $0 a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Deferred Revenue vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's Mar 2026 deferred revenue of $0 is the 2nd highest of the 8 companies compared; the peer median is $0.
  • Deferred revenue amounts to 0.0% of total assets for IPSC, versus a peer median of 0.0%.
IPSC Competitors Peer median
Deferred Revenue for IPSC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
COEPCoeptis Therapeutics, Inc.Mar 2026$485.68K -59.1%—2.5%
IPSCCentury Therapeutics, Inc.Mar 2026$0 ——0.0%
CUECue Biopharma, Inc.Mar 2026$0 ——0.0%
OTLKOutlook Therapeutics, Inc.Mar 2026$0 ——0.0%
EQEquillium, Inc.Mar 2026$0 ——0.0%
TELOTelomir Pharmaceuticals, Inc. Common StockMar 2026$0 ——0.0%
OSTXOS Therapies IncorporatedMar 2026$0 ——0.0%
KPTIKaryopharm Therapeutics Inc.Mar 2026$0 ——0.0%
Peer median (excluding IPSC) $0-59.1%—0.0%

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents56.45M84.27M47.32M58.44M61.85M
Short-term Investments166.43M231.23M125.41M130.85M55.26M
Net Receivables250K780K665K1.52M667K
Inventory00000
Other Current Assets2.79M462K1.79M860K2.99M
Total Current Assets228.15M319.72M176.99M194.05M120.77M
Property, Plant & Equipment (Net)69.82M111.73M92.08M90.85M66.17M
Goodwill00000
Intangible Assets00034.2M34.2M
Long-term Investments135.91M51.85M91.08M30.82M2.36M
Tax Assets00000
Other Non-current Assets3.49M3.24M541K3.3M211K
Total Non-current Assets209.22M166.82M183.7M159.17M102.94M
Total Assets437.38M486.54M360.69M353.22M223.7M
Account Payables7.6M5.45M2.74M3.08M4.77M
Short-term Debt1.04M6.5M1.51M00
Tax Payables00000
Deferred Revenue07.15M4.37M109.16M0
Other Current Liabilities1.08M3.17M2.72M82K3.78M
Total Current Liabilities15.66M29.82M17.85M129.78M20.23M
Long-term Debt8.9M3.74M000
Deferred Tax Liabilities0004.37M4.3M
Deferred Revenue (Non-current)0110.83M111.38M00
Other Non-current Liabilities2.02M718K56K8.74M0
Total Non-current Liabilities25.48M153.99M158.1M62.07M44.54M
Total Liabilities41.14M183.81M175.94M191.85M64.77M
Common Stock5K6K6K9K9K
Retained Earnings(388.17M)(519.1M)(655.77M)(782.34M)(791.92M)
Accumulated OCI(650K)(2.46M)108K324K30K
Other Stockholders Equity00000
Minority Interest00000
Total Equity396.24M302.74M184.75M161.36M158.94M
Total Debt25.12M49.41M48.17M53.83M43.57M
Net Debt(31.33M)(34.85M)847K(4.61M)(18.29M)

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.